Protocol Ledger

NCT06010693 · Phase III · COMPLETED

A Study of Daridorexant in Chinese Patients With Insomnia Disorder

Interventional Phase III clinical trial protocol NCT06010693 sponsored by Jiangsu Simcere Pharmaceutical Co in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-08-28 Enrollment: 206 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06010693
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)206 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06010693
Protocol FieldVerified Registry Value
NCT IdentifierNCT06010693
Consolidated Lead SponsorJiangsu Simcere Pharmaceutical Co
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment206 participants (ACTUAL)
Registered Start Date2023-08-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06010693
Hospital Research SiteLocationSite Profile
The First Affiliated Hospital Of Fujian Medical UniversityFuzhou, ChinaOpen Hospital Dossier ->
Guangdong Provincial People's HospitalGuangzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI